ABOUT RENTSCHLER BIOPHARMA
Rentschler Biopharma is a global leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, along with related consulting services, project management, and regulatory support. Its long-standing experience and commitment to quality are supported by a robust quality management system, operational excellence, and advanced technologies across all development and manufacturing stages. Rentschler Biopharma is a family-owned company with approximately 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, reinforcing its commitment to sustainability.
INDUSTRY INSIGHTS
-
![GettyImages-2199586285-scientist-gmp-compliance-quality]( "Fast Path To Market: Going From GMP1 To PPQ In Just 12 Months")
Learn how focused optimization and coordinated execution helped overcome technical uncertainty and enable faster progression to market readiness.
-
![cdmo-drug-assembly-manual-GettyImages-1339603591]( "Comprehensive Support From Early Development To Commercial Production")
Flexible development and manufacturing are essential for complex biologics. Explore scalable processes, advanced cell line strategies, and partnership models that move programs efficiently from early development to commercialization.
-
![Getty Images_ 2156307947_medical-trial-coding-clinical]( "Using Client Centricity As Fuel For Innovative Biologics Development And Manufacturing Solutions")
Complex biologics require flexible development, advanced analytics, and quality by design. Learn how collaborative bioprocessing reduces risk, enables efficient scale‑up, and supports clinical success.
-
![development-peptides-GettyImages-2176382458]( "Quality By Design Understanding And Securing Virus Clearance")
Data-driven virus clearance improves risk assessment, process insight, and study design. Learn how Quality by Design cuts late-stage risk while strengthening regulatory confidence and viral safety.
-
![cdmo-tech-transfer-GettyImages-2217587867]( "Seamless Tech Transfer, Predictable Outcomes Ensuring Success With A Dual-Site Model")
Technology transfer succeeds through trust, shared knowledge, and disciplined execution. See how collaboration, strong documentation, and digital tools reduce risk on the path to GMP.
CONTACT INFORMATION
Rentschler Biopharma
Erwin-Rentschler-Straße 21
Laupheim, D-88471
GERMANY
Phone: +49 7392 701-874
SOLUTIONS
-
![Rentschler Biopharma June 2026 Capabilities Update Cell Line Development]( "Rentschler Biopharma June 2026 Capabilities Update: Cell Line Development")
Next-gen CMC uses high-performing cell lines to accelerate timelines, improve consistency, and scale efficiently, leveraging gains in stability, pool quality, and process intensification.
-
![Rentschler Biopharma Capabilities Update May 2026 Large Molecule]( "Rentschler Biopharma Capabilities Update May 2026: Large Molecule")
Rentschler Biopharma is a global leading contract development and manufacturing organization (CDMO) focused exclusively on client projects.
-
![pharma-cmo-GettyImages-2193955683]( "Houston, We Have A Complex Biopharma Market! Taking Off With The Right CDMO")
Scientific innovation alone isn’t enough. Success requires smart development, adaptable strategies, and partners who manage pressure, supply risk, and tight timelines — while keeping quality central.
